|
| Ref | Study design | Duration | Treatment | Number of subjects | Inclusion criteria | Exclusion criteria | Assessment of the response |
|
| [25] | Randomized,
controlled | During
ovulation
induction
for ICSI | Treated group:
Myo-Ins 4 g + FA 400 µg/d
Control group:
FA 400 µg/d | Number = 60
Treated: 30
Control: 30 | Age: <40 years, PCOS, oligo/amenorrhea,
hyperandrogenism,
hyperandrogenemia,
typical features of ovaries on ultrasound scan | Hyperinsulinemia,
hyperprolactinemia,
hypothyroidism,
androgen excess due to
adrenal hyperplasia or
Cushing syndrome | E2, stimulation (days), FSH IU
Number of retrieved oocytes
Number of MII, number of immature oocytes
Number of embryos grade 1, embryo cleavage rate, fertilization rate
Number of biochemical pregnancies
Number of abortion cancellation rate
Ovarian hyperstimulation syndrome |
|
| [26] | Double-blind randomized
controlled | 12 weeks | Treated group:
Myo-Ins 4 g + FA 400 μg/d
Control group:
FA 400 μg/d | Number = 34
Treated: 17
Control: 17 | Age: <40 years, PCOS,
oligo/amenorrhea, hyperandrogenism,
hyperandrogenemia,
typical features of ovaries on ultrasound scan | Hypothyroidism,
hyperthyroidism,
diabetes mellitus,
androgen-secreting cancers,
adrenal hyperplasia,
Cushing syndrome | E2, total r-FSH
Number of follicles with a diameter >15 mm
Number of oocytes retrieved
Number of immature oocytes
Number of embryos grade 1
Number of transferred embryos
Number of biochemical pregnancies |
|
| [27] | Randomized,
controlled | 24 weeks | Treated group:
Myo-Ins 4 g + FA 400 µg/d
Control group:
metformin 1.5 g/d | Number = 120
Treated: 60
Control: 60 | Age: <35 years,
PCOS according to Rotterdam criteria | Hyperprolactinemia, hypothyroidism,
androgen excess,
adrenal hyperplasia or Cushing’s syndrome, tubal defects, semen parameters defects | Restoration of spontaneous ovarian activity by weekly serum P dosage and a transvaginal ultrasound scan documenting the presence of follicular growth or luteal cyst
Number of pregnancies
Abortion rate |
|
| [28] | Randomized
controlled | 8 weeks before r-FSH | Treated group:
D-chiro-Ins 300, 600, 1200, and 2400 mg/d
Control group:
placebo | Number = 54
Treated:
4 groups (10–12 pts)
Control: 11 | Age: <40 years,
PCOS according to Rotterdam criteria,
undergoing ICSI procedure | Insulin resistance
and/or hyperglycaemia | Total r-FSH, E2, stimulation (days)
Number of oocytes retrieved
Number of cycles cancelled
Number of MII, number of immature oocytes
Number of embryos grade 1 |
|
| [29] | Randomized
controlled | 8 weeks before r-FSH | Treated group:
Myo-Ins 4 g/d
Control group:
D-chiro-Ins 1.2 g/d | Number = 84
Treated: 43
Control: 41 | Age: <40 years,
PCOS according to Rotterdam criteria,
undergoing ICSI procedure | Insulin resistance
and/or hyperglycaemia | Duration of infertility, BMI, PRL, TSH, E2, stimulation (days), FSH
Number of cancelled cycles
Number of retrieved oocytes
Number of MII, number of immature oocytes
Number of embryos grade 1
Number of biochemical/clinical pregnancies
Number of spontaneous abortions |
|
| [30] | Randomized
controlled | 12 weeks before r-FSH | Treated group:
Myo-Ins 1.1 g + D-chiro-Ins 27.6 mg/d
Control group:
D-chiro-Ins 1 g/d | Number = 100
Treated: 47
Control: 53 | Age: ≤35 years, >35 years
BMI <28 kg/m2, FSH <10 IU/L
PCOS according to Rotterdam 2003 and a normal uterine cavity | Advanced stage (III or IV) endometriosis
Poor responders pts or suffering from premature ovarian failure | Total IU of r-FSH, E2 before hCG injection
Number of MII, number of VG-DEG
Number of embryos grade 1
Number of embryos transferred
Maturation rate and fertilization rate |
|
